MCID: OVR042
MIFTS: 82

Ovarian Cancer

Categories: Genetic diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Ovarian Cancer

MalaCards integrated aliases for Ovarian Cancer:

Name: Ovarian Cancer 53 12 72 49 24 71 36 28 51 40 3 14
Ovarian Carcinoma 49 24 13 51 69
Ovarian Neoplasm 12 28 69
Adenocarcinoma, Ovarian, Somatic 53 13
Epithelial Ovarian Cancer 71 69
Ovarian Cancer, Somatic 53 13
Primary Malignant Neoplasm of Ovary 69
Malignant Neoplasm of the Ovary 24
Malignant Tumor of the Ovary 24
Malignant Neoplasm of Ovary 69
Ovarian Carcinoma, Somatic 53
Malignant Tumour of Ovary 12
Malignant Ovarian Tumor 12
Primary Ovarian Cancer 12
Cancer of the Ovary 24
Tumor of the Ovary 12
Neoplasm of Ovary 28
Ovarian Neoplasms 41
Ovary Neoplasm 12
Oc 71

Characteristics:

OMIM:

53
Inheritance:
autosomal dominant


HPO:

31
ovarian cancer:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 53 167000
Disease Ontology 12 DOID:2394
ICD10 32 C56
ICD9CM 34 183.0
MeSH 41 D010051
NCIt 46 C4984 C7431
KEGG 36 H00027
SNOMED-CT via HPO 65 263681008 254838004 60718004

Summaries for Ovarian Cancer

NIH Rare Diseases : 49 Ovarian cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the ovaries. Many people with early ovarian cancer have no signs or symptoms of the condition. When present, symptoms are often nonspecific and blamed on other, more common conditions. Most cases of ovarian cancer occur sporadically in people with little to no family history of the condition; however, approximately 10-25% of ovarian cancers are thought to be "hereditary." Although the underlying genetic cause of some hereditary cases is unknown, many are part of a hereditary cancer syndrome (such as BRCA1 or BRCA2 hereditary breast and ovarian cancer syndrome, Lynch syndrome and Peutz-Jeghers syndrome) and are inherited in an autosomal dominant manner. The best treatment options for ovarian cancer depend on many factors including the subtype and stage of the condition, but may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy). Last updated: 3/30/2015

MalaCards based summary : Ovarian Cancer, also known as ovarian carcinoma, is related to ovarian cancer 1 and hereditary breast ovarian cancer syndrome, and has symptoms including abnormality of metabolism/homeostasis, breast carcinoma and dysgerminoma. An important gene associated with Ovarian Cancer is OPCML (Opioid Binding Protein/Cell Adhesion Molecule Like), and among its related pathways/superpathways are MicroRNAs in cancer and HIV Life Cycle. The drugs CEA-Scan and Doxil have been mentioned in the context of this disorder. Affiliated tissues include breast, ovary and testes, and related phenotypes are Decreased viability and Decreased viability

OMIM : 53 Ovarian cancer, the leading cause of death from gynecologic malignancy, is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of visceral metastases (Chi et al., 2001). These typical features relate to the biology of the disease, which is a principal determinant of outcome (Auersperg et al., 2001). Epithelial ovarian cancer is the most common form and encompasses 5 major histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Epithelial ovarian cancer arises as a result of genetic alterations sustained by the ovarian surface epithelium (Stany et al., 2008; Soslow, 2008). (167000)

UniProtKB/Swiss-Prot : 71 Ovarian cancer: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.

MedlinePlus : 40 The ovaries are part of the female reproductive system. They produce a woman's eggs and female hormones. Each ovary is about the size and shape of an almond. Cancer of the ovary is not common, but it causes more deaths than other female reproductive cancers. The sooner ovarian cancer is found and treated, the better your chance for recovery. But ovarian cancer is hard to detect early. Women with ovarian cancer may have no symptoms or just mild symptoms until the disease is in an advanced stage. Then it is hard to treat. Symptoms may include A heavy feeling in the pelvis Pain in the lower abdomen Bleeding from the vagina Weight gain or loss Abnormal periods Unexplained back pain that gets worse Gas, nausea, vomiting, or loss of appetite To diagnose ovarian cancer, doctors do one or more tests. They include a physical exam, a pelvic exam, lab tests, ultrasound, or a biopsy. Treatment is usually surgery followed by chemotherapy. NIH: National Cancer Institute

CDC : 3 Cancer is a disease in which abnormal cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later.

Genetics Home Reference : 24 Ovarian cancer is a disease that affects women. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.

Disease Ontology : 12 A female reproductive organ cancer that is located in the ovary.

Novus Biologicals : 52 Tumor markers can be found in the body when cancer is present. They are most often found in the blood or urine, but can also be found in tumors and other tissues. High level of the tumor marker CA125 in the blood strongly suggests ovarian cancer. CA125 is an antigen present on 80% of non-mucinous ovarian carcinomas.

Wikipedia : 72 Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the... more...

Related Diseases for Ovarian Cancer

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1 Ovarian Benign Neoplasm

Diseases related to Ovarian Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 352)
# Related Disease Score Top Affiliating Genes
1 ovarian cancer 1 35.2 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 DPH1
2 hereditary breast ovarian cancer syndrome 35.0 BRCA1 BRCA2 BRIP1 PALB2
3 brca1 hereditary breast and ovarian cancer syndrome 34.7 BRCA1 BRCA2
4 breast-ovarian cancer, familial 1 34.6 BRCA1 BRCA2
5 hereditary site-specific ovarian cancer syndrome 34.3 BRCA1 BRCA2
6 pancreatic cancer 33.7 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 EGFR
7 breast cancer 33.6 AKT1 BRCA1 BRCA2 BRIP1 CDH1 CTNNB1
8 lynch syndrome 33.3 BRCA1 BRCA2 CTNNB1 KRAS
9 ovary epithelial cancer 33.0 AKT1 BRCA1 BRCA2 CDH1 ERBB2 KRAS
10 adenocarcinoma 31.8 AKT1 CDH1 CTNNB1 EGFR ERBB2 KRAS
11 primary peritoneal carcinoma 31.7 BRCA1 BRCA2 EGFR ERBB2 MUC16
12 colorectal cancer 31.6 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 EGFR
13 endometrial cancer 31.3 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 EGFR
14 prostate cancer 31.2 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 EGFR
15 wilms tumor 1 31.1 BRCA2 CTNNB1 ERBB2 KRAS
16 papillary carcinoma 31.0 CDH1 ERBB2 MUC1
17 pseudo-meigs syndrome 31.0 CDH1 MUC16
18 cystadenocarcinoma 31.0 AKT1 MUC1 MUC16
19 fanconi anemia, complementation group a 30.9 BRCA1 BRCA2 BRIP1 PALB2
20 glioblastoma 30.9 AKT1 BRCA2 EGFR ERBB2 PIK3CA
21 mucinous adenocarcinoma 30.9 EGFR KRAS MUC1
22 cystadenofibroma 30.8 BRCA1 BRCA2 MUC1
23 papillary adenocarcinoma 30.8 CDH1 ERBB2 MUC1
24 li-fraumeni syndrome 30.8 BRCA1 BRCA2 EGFR
25 breast carcinoma in situ 30.8 BRCA1 BRCA2 ERBB2
26 sporadic breast cancer 30.7 BRCA1 BRCA2 ERBB2
27 malignant peritoneal mesothelioma 30.7 EGFR MUC1
28 bladder cancer 30.5 CDH1 EGFR ERBB2 KRAS MUC1
29 brca2 hereditary breast and ovarian cancer syndrome 12.2
30 breast-ovarian cancer, familial 2 12.2
31 breast-ovarian cancer, familial 3 12.2
32 breast-ovarian cancer, familial 4 12.2
33 childhood ovarian cancer 12.2
34 familiar ovarian carcinoma 11.8
35 paraneoplastic cerebellar degeneration 11.3
36 endometrioid ovary carcinoma 11.3
37 female reproductive organ cancer 11.2 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 EGFR
38 reproductive organ cancer 11.2 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 EGFR
39 ductal carcinoma in situ 11.2 AKT1 BRCA1 BRCA2 CDH1 EGFR ERBB2
40 ovarian disease 11.2
41 papillary serous adenocarcinoma 11.2
42 malignant ovarian surface epithelial-stromal neoplasm 11.2 AKT1 BRCA1 BRCA2 CDH1 ERBB2 KRAS
43 pancreas adenocarcinoma 11.1 AKT1 BRCA2 CDH1 CTNNB1 EGFR KRAS
44 esophageal cancer 11.1 AKT1 CDH1 CTNNB1 EGFR ERBB2 KRAS
45 gastric cancer 11.1 AKT1 CDH1 CTNNB1 EGFR ERBB2 KRAS
46 gastrointestinal system cancer 11.1 AKT1 CDH1 CTNNB1 EGFR ERBB2 KRAS
47 pre-malignant neoplasm 11.1 BRCA1 BRCA2 CDH1 EGFR ERBB2
48 lobular neoplasia 11.1 BRCA1 CDH1 CTNNB1 ERBB2 MUC1
49 pancreatic ductal adenocarcinoma 11.1 AKT1 CDH1 CTNNB1 EGFR ERBB2 KRAS
50 breast ductal carcinoma 11.1 BRCA1 CDH1 CTNNB1 EGFR ERBB2

Comorbidity relations with Ovarian Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Fallopian Tube Carcinoma Hydronephrosis
Intestinal Obstruction Myofibroma
Neutropenia Paralytic Ileus
Peritoneum Cancer Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Ovarian Cancer:



Diseases related to Ovarian Cancer

Symptoms & Phenotypes for Ovarian Cancer

Symptoms via clinical synopsis from OMIM:

53
Oncology:
ovarian cancer
dysgerminoma
ovarian papillary adenocarcinoma
serous ovarian cystadenocarcinoma
breast cancer

Lab:
frequent loss of heterozygosity at 6q24-q27


Clinical features from OMIM:

167000

Human phenotypes related to Ovarian Cancer:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis 31 HP:0001939
2 breast carcinoma 31 HP:0003002
3 dysgerminoma 31 HP:0100621
4 ovarian papillary adenocarcinoma 31 HP:0006774

UMLS symptoms related to Ovarian Cancer:


pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer according to GeneCards Suite gene sharing:

25 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.37 KRAS MUC1 PIK3CA EGFR
2 Decreased viability GR00106-A-0 10.37 KRAS
3 Decreased viability GR00221-A-1 10.37 KRAS AKT1 PIK3CA CDH1 EGFR
4 Decreased viability GR00221-A-2 10.37 KRAS AKT1 PIK3CA
5 Decreased viability GR00221-A-3 10.37 AKT1
6 Decreased viability GR00221-A-4 10.37 AKT1 PIK3CA EGFR
7 Decreased viability GR00301-A 10.37 KRAS CDH1
8 Decreased viability GR00381-A-1 10.37 KRAS
9 Decreased cell migration GR00055-A-1 9.73 KRAS AKT1 MUC1 PIK3CA CTNNB1 EGFR
10 Decreased viability with cisplatin GR00101-A-4 9.13 BRCA1 BRCA2 BRIP1
11 Synthetic lethal with cisplatin GR00101-A-1 8.8 BRCA1 BRCA2 BRIP1

MGI Mouse Phenotypes related to Ovarian Cancer:

43 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.41 CDH1 AKT1 BRCA2 BRCA1 BRIP1 DPH1
2 homeostasis/metabolism MP:0005376 10.36 BRCA1 AKT1 BRCA2 BRIP1 CDH1 DPH1
3 growth/size/body region MP:0005378 10.34 BRCA1 AKT1 BRCA2 CDH1 DPH1 CTNNB1
4 cardiovascular system MP:0005385 10.32 BRCA1 AKT1 CDH1 CTNNB1 EGFR KRAS
5 embryo MP:0005380 10.29 AKT1 BRCA2 BRCA1 CDH1 DPH1 CTNNB1
6 endocrine/exocrine gland MP:0005379 10.28 AKT1 BRCA2 BRCA1 BRIP1 CDH1 CTNNB1
7 integument MP:0010771 10.27 CDH1 AKT1 BRCA2 BRCA1 DPH1 CTNNB1
8 mortality/aging MP:0010768 10.27 BRCA1 AKT1 BRCA2 CTNNB1 CDH1 DPH1
9 neoplasm MP:0002006 10.25 CDH1 AKT1 BRCA2 BRCA1 BRIP1 DPH1
10 nervous system MP:0003631 10.18 AKT1 BRCA2 BRCA1 BRIP1 DPH1 CTNNB1
11 digestive/alimentary MP:0005381 10.16 BRCA1 BRCA2 EGFR CDH1 DPH1 CTNNB1
12 limbs/digits/tail MP:0005371 10.08 BRCA2 BRCA1 DPH1 CTNNB1 EGFR KRAS
13 muscle MP:0005369 10.03 BRCA1 AKT1 EGFR CTNNB1 KRAS ERBB2
14 normal MP:0002873 9.97 BRCA1 AKT1 BRCA2 EGFR CDH1 CTNNB1
15 reproductive system MP:0005389 9.85 BRCA1 AKT1 BRCA2 BRIP1 CDH1 CTNNB1
16 pigmentation MP:0001186 9.65 BRCA1 CTNNB1 DPH1 EGFR KRAS
17 respiratory system MP:0005388 9.61 AKT1 BRCA1 DPH1 CTNNB1 EGFR KRAS
18 skeleton MP:0005390 9.36 AKT1 BRCA2 BRCA1 DPH1 CTNNB1 EGFR

Drugs & Therapeutics for Ovarian Cancer

FDA approved drugs:

(show all 6)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
CEA-Scan 17 Immunomedics April 1996
2
Doxil 17 45 DOXORUBICIN HYDROCHLORIDE Alza June 1999
3
Ethyol 17 AMIFOSTINE Alza December 8, 1995
4
Hycamtin 17 45 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/May 1996
5
Iressa 17 45 GEFITINIB AstraZeneca May 2003
6
Lynparza 17 45 OLAPARIB AstraZeneca December 2014

Drugs for Ovarian Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 620)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-02-2 5743
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 763113-22-0 23725625
4
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
5
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
6
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
7
Tranexamic Acid Approved Phase 4 1197-18-8 5526
8
Aprepitant Approved, Investigational Phase 4,Phase 2 170729-80-3 6918365 151165
9
Fosaprepitant Approved Phase 4,Phase 2 172673-20-0 219090
10
Iron Approved Phase 4,Phase 2 7439-89-6 23925
11
Peppermint Approved, Nutraceutical Phase 4
12
Vitamin C Approved, Nutraceutical Phase 4,Phase 1,Phase 2 50-81-7 54670067 5785
13
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 68-26-8, 11103-57-4 445354
14
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
15
Substance P Investigational Phase 4,Phase 2 33507-63-0 44359816
16 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
17 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
18 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
19 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
20 BB 1101 Phase 4,Phase 3,Phase 1,Phase 2
21 Dexamethasone acetate Phase 4,Phase 3,Phase 1,Phase 2 1177-87-3
22 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
29 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Poly(ADP-ribose) Polymerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 taxane Phase 4,Phase 3,Phase 2,Phase 1
33 Ferrous fumarate Phase 4,Early Phase 1
34 Micronutrients Phase 4,Phase 3,Phase 1,Phase 2
35 Trace Elements Phase 4,Phase 3,Phase 1,Phase 2
36 Vitamins Phase 4,Phase 3,Phase 1,Phase 2
37 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1
38 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
39 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
42 Antifibrinolytic Agents Phase 4
43 Coagulants Phase 4,Phase 2
44 Hemostatics Phase 4,Phase 2
45 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
47 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
48
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
49 neurokinin A Phase 4,Phase 2
50 Neurokinin-1 Receptor Antagonists Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 2241)

# Name Status NCT ID Phase Drugs
1 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
2 Tranexamic Acid in Surgery of Advanced Ovarian Cancer Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
3 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
4 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
5 PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
6 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
7 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
8 Guilford Genomic Medicine Initiative (GGMI) Completed NCT01372553 Phase 4
9 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
10 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
11 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
12 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Recruiting NCT02476968 Phase 4 Olaparib
13 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
14 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Recruiting NCT01953107 Phase 4
15 Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab Active, not recruiting NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
16 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Not yet recruiting NCT03349463 Phase 4 Fluciclovine F18
17 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
18 Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
19 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
20 Hydralazine Valproate for Ovarian Cancer Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
21 Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
22 Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
23 Lymphadenectomy In Ovarian Neoplasms Unknown status NCT00712218 Phase 3
24 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
25 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
26 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
27 Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study Unknown status NCT00715286 Phase 3
28 Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
29 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
30 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
31 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
32 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
33 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
34 Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy Unknown status NCT02097446 Phase 3
35 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
36 A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Completed NCT01847274 Phase 3 Active comparator: Niraparib;placebo
37 Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse Completed NCT00849667 Phase 3 MORAb-003 (farletuzumab);MORAb-003 (farletuzumab);0.9% Saline
38 Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy Completed NCT00312988 Phase 3 Hycamtin;Gemcitabine
39 Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan
40 An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer Completed NCT00113607 Phase 3 Trabectedin;DOXIL;Dexamethasone
41 Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer Completed NCT00102375 Phase 3 Topotecan
42 Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites Completed NCT00327444 Phase 2, Phase 3 aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);Placebo;aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
43 A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
44 Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer Completed NCT00102414 Phase 3 Gemcitabine
45 Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane Completed NCT02728622 Phase 3 Tamoxifen;Chemotherapy
46 Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) Completed NCT01684878 Phase 3 Gemcitabine (Chemotherapy);Paclitaxel (Chemotherapy);Pertuzumab;Placebo;Topotecan (Chemotherapy)
47 Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer Completed NCT00003695 Phase 3 chemotherapy
48 Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer Completed NCT00426257 Phase 3
49 Women's Activity and Lifestyle Study in Connecticut Completed NCT02107066 Phase 3
50 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3

Search NIH Clinical Center for Ovarian Cancer

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: ovarian neoplasms

Genetic Tests for Ovarian Cancer

Genetic tests related to Ovarian Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of Ovary 28 AKT1 CDH1 CTNNB1 OPCML PIK3CA PRKN
2 Ovarian Cancer 28
3 Ovarian Neoplasm 28

Anatomical Context for Ovarian Cancer

MalaCards organs/tissues related to Ovarian Cancer:

38
Breast, Ovary, Testes, Lung, T Cells, Endothelial, Prostate

The Foundational Model of Anatomy Ontology organs/tissues related to Ovarian Cancer:

18
The Ovary

Publications for Ovarian Cancer

Articles related to Ovarian Cancer:

(show top 50) (show all 6667)
# Title Authors Year
1
Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement. ( 29450531 )
2018
2
Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells. ( 29436692 )
2018
3
The ubiquitin ligase TRIM56 inhibits ovarian cancer progression by targeting vimentin. ( 28771721 )
2018
4
Screening for Ovarian Cancer. ( 29450526 )
2018
5
miR-144 Potentially Suppresses Proliferation and Migration of Ovarian Cancer Cells by Targeting RUNX1. ( 29445078 )
2018
6
High ALDH activity defines ovarian cancer stem-like cells with enhanced invasiveness and EMT progress which are responsible for tumor invasion. ( 29170132 )
2018
7
Retroperitoneal lymphadenectomy for ovarian cancer with double inferior vena cava. ( 29307453 )
2018
8
MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis. ( 29452092 )
2018
9
Screening for Ovarian Cancer in Asymptomatic Women. ( 29450509 )
2018
10
Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer. ( 29400022 )
2018
11
Precise preoperative diagnosis of struma ovarii with pseudo-Meigs' syndrome mimicking ovarian cancer with the combination of<sup>131</sup>I scintigraphy and<sup>18</sup>F-FDG PET: case report and review of the literature. ( 29391043 )
2018
12
Is There a Future for Ovarian Cancer Screening? ( 29450456 )
2018
13
Preoperative Anti-Class III I^-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer. ( 29448203 )
2018
14
GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. ( 28542798 )
2018
15
Lymphedema in ovarian cancer survivors: Assessing diagnostic methods and the effects of physical activity. ( 29437202 )
2018
16
Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. ( 29447163 )
2018
17
Palmar fasciitis with polyarthritis-associated ovarian cancer: Case report and literature review. ( 29435290 )
2018
18
A Miniature Cell Pattern Formation of Ovarian Cancer Cell Lines on Self-Assembling Peptide Nanofiber-Coated Coverslip and<i>In Vitro</i>Chemosensitivity Assay. ( 29442905 )
2018
19
Anti-transcription intermediary factor 1I^ antibody titer correlates with clinical symptoms in a patient with recurrent dermatomyositis associated with ovarian cancer. ( 29341447 )
2018
20
The Yet Unrealized Promise of Ovarian Cancer Screening. ( 29450480 )
2018
21
Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. ( 29450530 )
2018
22
Downregulation of SPINK13 Promotes Metastasis by Regulating uPA in Ovarian Cancer Cells. ( 29439245 )
2018
23
Correlation of Pyruvate Kinase M2 Expression with Clinicopathological Data in Ovarian Cancer. ( 29277786 )
2018
24
Confounders other than comorbidity explain survival differences in Danish and Swedish ovarian cancer patients - a comparative cohort study. ( 29451070 )
2018
25
miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8. ( 29436681 )
2018
26
Flavonoids from Chinese bayberry leaves induced apoptosis and G1 cell cycle arrest via Erk pathway in ovarian cancer cells. ( 29438890 )
2018
27
Steroid metabolism gene polymorphisms and their implications on breast and ovarian cancer prognosis. ( 28692125 )
2017
28
Silencing of Apurinic/Apyrimidinic Endonuclease 1 Inhibits the Growth and Migration in Ovarian Cancer Cell via Activator-Protein-1 Signaling. ( 27553367 )
2017
29
Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies. ( 28521614 )
2017
30
Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer. ( 28414925 )
2017
31
RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance. ( 28806395 )
2017
32
MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3. ( 27887917 )
2017
33
IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer. ( 28993412 )
2017
34
Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. ( 27292260 )
2017
35
LAMP3 expression correlated with poor clinical outcome in human ovarian cancer. ( 28349821 )
2017
36
Hospital readmission after ovarian cancer surgery: Are we measuring surgical quality? ( 28522108 )
2017
37
INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer. ( 28436941 )
2017
38
MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells. ( 28817834 )
2017
39
SEI1 induces genomic instability by inhibiting DNA damage response in ovarian cancer. ( 27697611 )
2017
40
A loop of cancer-stroma-cancer interaction promotes peritoneal metastasis of ovarian cancer via TNFI+-TGFI+-EGFR. ( 28166193 )
2017
41
MARCH5 RNA promotes autophagy, migration, and invasion of ovarian cancer cells. ( 27875077 )
2017
42
Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies. ( 28710511 )
2017
43
Sucrose Non-Fermenting Related Kinase Expression in Ovarian Cancer and Correlation with Clinical Features. ( 28722495 )
2017
44
Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells. ( 28278050 )
2017
45
Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. ( 28513088 )
2017
46
A multi-gene panel study in hereditary breast and ovarian cancer in Colombia. ( 28528518 )
2017
47
Role of CYP1A1 in the biological activity of methylated resveratrol analogue, 3,4,5,4'-tetramethoxystilbene (DMU-212) in ovarian cancer A-2780 and non-cancerous HOSE cells. ( 28049037 )
2017
48
Ginsenoside 20(S)-Rg3 suppresses ovarian cancer migration via hypoxia-inducible factor 1 alpha and nuclear factor-kappa B signals. ( 28459376 )
2017
49
Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-I^ signaling. ( 28064471 )
2017
50
Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer. ( 27928164 )
2017

Variations for Ovarian Cancer

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Cancer:

71
# Symbol AA change Variation ID SNP ID
1 BRCA1 p.Cys61Gly VAR_007757 rs28897672
2 BRCA1 p.Cys1697Arg VAR_020702 rs80356993
3 BRCA1 p.Arg1699Trp VAR_075666 rs55770810
4 CTNNB1 p.Ser37Cys VAR_017625 rs121913403
5 CTNNB1 p.Thr41Ile VAR_017630 rs121913413
6 OPCML p.Pro95Arg VAR_055421 rs137852691
7 PIK3CA p.His1047Arg VAR_026192 rs121913279

ClinVar genetic disease variations for Ovarian Cancer:

6 (show top 50) (show all 76)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
2 OPCML NM_001012393.2(OPCML): c.263C> G (p.Pro88Arg) single nucleotide variant Pathogenic rs137852691 GRCh37 Chromosome 11, 132527098: 132527098
3 RRAS2 NM_001177314.1(RRAS2): c.110A> T (p.Gln37Leu) single nucleotide variant Pathogenic rs113954997 GRCh37 Chromosome 11, 14316390: 14316390
4 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
5 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
6 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
7 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
8 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
9 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
10 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
11 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
12 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
13 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
14 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
15 ERBB2 NM_001005862.2(ERBB2): c.2480A> G (p.Asn827Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28933370 GRCh37 Chromosome 17, 37881378: 37881378
16 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic/Likely pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
17 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
18 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
19 CTNNB1 NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
20 CTNNB1 NM_001904.3(CTNNB1): c.101G> A (p.Gly34Glu) single nucleotide variant Pathogenic/Likely pathogenic rs28931589 GRCh37 Chromosome 3, 41266104: 41266104
21 CTNNB1 NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
22 BRCA1 NM_007294.3(BRCA1): c.5266dupC (p.Gln1756Profs) duplication Pathogenic rs80357906 GRCh37 Chromosome 17, 41209082: 41209082
23 PIK3CA NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913272 GRCh38 Chromosome 3, 179210192: 179210192
24 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
25 BRCA1 NM_007294.3(BRCA1): c.1687C> T (p.Gln563Ter) single nucleotide variant Pathogenic rs80356898 GRCh37 Chromosome 17, 41245861: 41245861
26 BRCA2 NM_000059.3(BRCA2): c.5682C> G (p.Tyr1894Ter) single nucleotide variant Pathogenic rs41293497 GRCh37 Chromosome 13, 32914174: 32914174
27 KRAS NM_033360.3(KRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
28 PIK3CA NM_006218.3(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
29 BRCA2 NM_000059.3(BRCA2): c.7806-2A> G single nucleotide variant Pathogenic/Likely pathogenic rs81002836 GRCh37 Chromosome 13, 32936658: 32936658
30 BRCA1 NM_007294.3(BRCA1): c.3375_3376delTC (p.Pro1126Ilefs) deletion Pathogenic rs80357828 GRCh37 Chromosome 17, 41244172: 41244173
31 BRCA1 NM_007294.3(BRCA1): c.5095C> T (p.Arg1699Trp) single nucleotide variant Pathogenic rs55770810 GRCh37 Chromosome 17, 41215948: 41215948
32 PALB2 NM_024675.3(PALB2): c.1050_1053delAACA (p.Thr351Argfs) deletion Pathogenic rs515726060 GRCh38 Chromosome 16, 23635493: 23635496
33 BRIP1 NM_032043.2(BRIP1): c.2038_2039dupTT (p.Leu680Phefs) duplication Pathogenic/Likely pathogenic rs587778134 GRCh37 Chromosome 17, 59853820: 59853821
34 BRIP1 NM_032043.2(BRIP1): c.2273dupT (p.Ala759Serfs) duplication Pathogenic/Likely pathogenic rs587780236 GRCh37 Chromosome 17, 59820480: 59820480
35 BRIP1 NM_032043.2(BRIP1): c.1871C> A (p.Ser624Ter) single nucleotide variant Pathogenic rs587781321 GRCh38 Chromosome 17, 61780325: 61780325
36 BRIP1 NM_032043.2(BRIP1): c.1240C> T (p.Gln414Ter) single nucleotide variant Pathogenic/Likely pathogenic rs368796923 GRCh37 Chromosome 17, 59876561: 59876561
37 BRIP1 NM_032043.2(BRIP1): c.1853_1854insG (p.Pro619Thrfs) insertion Pathogenic/Likely pathogenic rs587781985 GRCh37 Chromosome 17, 59857703: 59857704
38 BRIP1 NM_032043.2(BRIP1): c.2765T> G (p.Leu922Ter) single nucleotide variant Pathogenic rs587782410 GRCh37 Chromosome 17, 59763337: 59763337
39 NC_012920.1: m.14743A> G single nucleotide variant Likely pathogenic rs527236161 GRCh37 Chromosome MT, 14743: 14743
40 MT-CYB NC_012920.1: m.14753C> T single nucleotide variant Likely pathogenic rs527236162 GRCh38 Chromosome MT, 14753: 14753
41 MT-CYB NC_012920.1: m.14784T> C single nucleotide variant Likely pathogenic rs527236163 GRCh37 Chromosome MT, 14784: 14784
42 MT-CYB NC_012920.1: m.15058C> T single nucleotide variant Likely pathogenic rs527236171 GRCh37 Chromosome MT, 15058: 15058
43 MT-CYB NC_012920.1: m.15098A> G single nucleotide variant Likely pathogenic rs527236172 GRCh37 Chromosome MT, 15098: 15098
44 MT-CYB NC_012920.1: m.15314G> A single nucleotide variant Likely pathogenic rs527236176 GRCh37 Chromosome MT, 15314: 15314
45 MT-CYB NC_012920.1: m.15328A> G single nucleotide variant Likely pathogenic rs527236178 GRCh37 Chromosome MT, 15328: 15328
46 MT-CYB NC_012920.1: m.15334C> T single nucleotide variant Likely pathogenic rs527236179 GRCh37 Chromosome MT, 15334: 15334
47 MT-CYB NC_012920.1: m.15363A> G single nucleotide variant Likely pathogenic rs527236182 GRCh37 Chromosome MT, 15363: 15363
48 MT-CYB NC_012920.1: m.15453T> C single nucleotide variant Likely pathogenic rs527236184 GRCh37 Chromosome MT, 15453: 15453
49 MT-CYB NC_012920.1: m.15459C> T single nucleotide variant Likely pathogenic rs527236186 GRCh37 Chromosome MT, 15459: 15459
50 MT-CYB NC_012920.1: m.15884G> A single nucleotide variant Likely pathogenic rs527236195 GRCh37 Chromosome MT, 15884: 15884

Cosmic variations for Ovarian Cancer:

9 (show all 32)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM11582 TP53 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 19
2 COSM10663 TP53 ovary,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 19
3 COSM11066 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 19
4 COSM10738 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 19
5 COSM11148 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 19
6 COSM14135 SMAD4 ovary,NS,carcinoma,adenocarcinoma c.1051G>C p.D351H 19
7 COSM766 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1636C>A p.Q546K 19
8 COSM760 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1624G>A p.E542K 19
9 COSM564 NRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 19
10 COSM580 NRAS ovary,NS,carcinoma,adenocarcinoma c.181C>A p.Q61K 19
11 COSM522 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>C p.G12A 19
12 COSM520 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>T p.G12V 19
13 COSM53265 EGFR ovary,NS,carcinoma,adenocarcinoma c.2556G>T p.K852N 19
14 COSM22992 EGFR ovary,NS,carcinoma,adenocarcinoma c.2161G>A p.G721S 19
15 COSM53264 EGFR ovary,NS,carcinoma,adenocarcinoma c.2174C>T p.T725M 19
16 COSM53235 EGFR ovary,NS,carcinoma,adenocarcinoma c.2481C>T p.Y827Y 19
17 COSM53226 EGFR ovary,NS,carcinoma,adenocarcinoma c.2099A>G p.N700S 19
18 COSM28286 EGFR ovary,NS,carcinoma,adenocarcinoma c.2494C>T p.R832C 19
19 COSM53228 EGFR ovary,NS,carcinoma,adenocarcinoma c.2123A>G p.K708R 19
20 COSM53227 EGFR ovary,NS,carcinoma,adenocarcinoma c.2506C>A p.R836S 19
21 COSM6224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2573T>G p.L858R 19
22 COSM53230 EGFR ovary,NS,carcinoma,adenocarcinoma c.2597A>G p.E866G 19
23 COSM28511 EGFR ovary,NS,carcinoma,adenocarcinoma c.2108T>C p.L703P 19
24 COSM53225 EGFR ovary,NS,carcinoma,adenocarcinoma c.2112G>A p.L704L 19
25 COSM53232 EGFR ovary,NS,carcinoma,adenocarcinoma c.2122A>G p.K708E 19
26 COSM53266 EGFR ovary,NS,carcinoma,adenocarcinoma c.2165C>T p.A722V 19
27 COSM53224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2173A>G p.T725A 19
28 COSM53213 EGFR ovary,NS,carcinoma,adenocarcinoma c.2604A>T p.E868D 19
29 COSM53229 EGFR ovary,NS,carcinoma,adenocarcinoma c.2232C>A p.I744I 19
30 COSM53231 EGFR ovary,NS,carcinoma,adenocarcinoma c.2559C>T p.I853I 19
31 COSM12373 EGFR ovary,NS,carcinoma,adenocarcinoma c.2159C>T p.S720F 19
32 COSM22499 ATM ovary,NS,carcinoma,adenocarcinoma c.1810C>T p.P604S 19

Copy number variations for Ovarian Cancer from CNVD:

7 (show top 50) (show all 8010)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13413 1 1 23549970 Deletion AADACL3 Ovarian cancer
2 13414 1 1 23549970 Deletion AADACL4 Ovarian cancer
3 13415 1 1 23549970 Deletion ACAP3 Ovarian cancer
4 13416 1 1 23549970 Deletion ACOT7 Ovarian cancer
5 13417 1 1 23549970 Deletion ACTL8 Ovarian cancer
6 13418 1 1 23549970 Deletion ACTRT2 Ovarian cancer
7 13419 1 1 23549970 Deletion AGMAT Ovarian cancer
8 13420 1 1 23549970 Deletion AGRN Ovarian cancer
9 13421 1 1 23549970 Deletion AGTRAP Ovarian cancer
10 13422 1 1 23549970 Deletion AJAP1 Ovarian cancer
11 13423 1 1 23549970 Deletion AKR7A2 Ovarian cancer
12 13424 1 1 23549970 Deletion AKR7A3 Ovarian cancer
13 13425 1 1 23549970 Deletion AKR7L Ovarian cancer
14 13426 1 1 23549970 Deletion ALDH4A1 Ovarian cancer
15 13427 1 1 23549970 Deletion ALPL Ovarian cancer
16 13428 1 1 23549970 Deletion ANGPTL7 Ovarian cancer
17 13429 1 1 23549970 Deletion APITD1 Ovarian cancer
18 13430 1 1 23549970 Deletion ARHGEF10L Ovarian cancer
19 13431 1 1 23549970 Deletion ARHGEF16 Ovarian cancer
20 13432 1 1 23549970 Deletion ARHGEF19 Ovarian cancer
21 13433 1 1 23549970 Deletion ATAD3A Ovarian cancer
22 13434 1 1 23549970 Deletion ATAD3B Ovarian cancer
23 13435 1 1 23549970 Deletion ATAD3C Ovarian cancer
24 13436 1 1 23549970 Deletion ATP13A2 Ovarian cancer
25 13437 1 1 23549970 Deletion AURKAIP1 Ovarian cancer
26 13438 1 1 23549970 Deletion B3GALT6 Ovarian cancer
27 13439 1 1 23549970 Deletion C1QA Ovarian cancer
28 13440 1 1 23549970 Deletion C1QB Ovarian cancer
29 13441 1 1 23549970 Deletion C1QC Ovarian cancer
30 13442 1 1 23549970 Deletion C1orf126 Ovarian cancer
31 13443 1 1 23549970 Deletion C1orf127 Ovarian cancer
32 13444 1 1 23549970 Deletion C1orf144 Ovarian cancer
33 13445 1 1 23549970 Deletion C1orf151 Ovarian cancer
34 13446 1 1 23549970 Deletion C1orf158 Ovarian cancer
35 13447 1 1 23549970 Deletion C1orf159 Ovarian cancer
36 13448 1 1 23549970 Deletion C1orf170 Ovarian cancer
37 13449 1 1 23549970 Deletion C1orf174 Ovarian cancer
38 13450 1 1 23549970 Deletion C1orf187 Ovarian cancer
39 13451 1 1 23549970 Deletion C1orf200 Ovarian cancer
40 13452 1 1 23549970 Deletion C1orf64 Ovarian cancer
41 13453 1 1 23549970 Deletion C1orf70 Ovarian cancer
42 13454 1 1 23549970 Deletion C1orf86 Ovarian cancer
43 13455 1 1 23549970 Deletion C1orf89 Ovarian cancer
44 13456 1 1 23549970 Deletion C1orf93 Ovarian cancer
45 13457 1 1 23549970 Deletion CA6 Ovarian cancer
46 13458 1 1 23549970 Deletion CALML6 Ovarian cancer
47 13459 1 1 23549970 Deletion CAMK2N1 Ovarian cancer
48 13460 1 1 23549970 Deletion CAMTA1 Ovarian cancer
49 13461 1 1 23549970 Deletion CAPZB Ovarian cancer
50 13462 1 1 23549970 Deletion CASP9 Ovarian cancer

Expression for Ovarian Cancer

Search GEO for disease gene expression data for Ovarian Cancer.

Pathways for Ovarian Cancer

Pathways related to Ovarian Cancer according to KEGG:

36
# Name Kegg Source Accession
1 MicroRNAs in cancer hsa05206

Pathways related to Ovarian Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.78 AKT1 CDH1 CTNNB1 EGFR ERBB2 KRAS
2
Show member pathways
13.6 AKT1 BRCA1 CDH1 EGFR ERBB2 KRAS
3
Show member pathways
13.36 AKT1 CDH1 CTNNB1 EGFR ERBB2 KRAS
4
Show member pathways
13.34 AKT1 CDH1 CTNNB1 EGFR ERBB2 KRAS
5
Show member pathways
13.04 AKT1 BRCA1 CTNNB1 EGFR KRAS PIK3CA
6
Show member pathways
13.01 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 EGFR
7
Show member pathways
12.99 AKT1 BRCA1 BRCA2 BRIP1 KRAS RRAS2
8
Show member pathways
12.94 AKT1 CTNNB1 EGFR ERBB2 KRAS PIK3CA
9 12.82 AKT1 BRCA2 CDH1 CTNNB1 EGFR ERBB2
10
Show member pathways
12.78 AKT1 EGFR ERBB2 KRAS PIK3CA
11
Show member pathways
12.76 AKT1 CDH1 CTNNB1 ERBB2 KRAS PIK3CA
12
Show member pathways
12.73 AKT1 CDH1 CTNNB1 EGFR KRAS PIK3CA
13
Show member pathways
12.72 AKT1 CTNNB1 EGFR KRAS PIK3CA
14
Show member pathways
12.64 AKT1 EGFR ERBB2 KRAS PIK3CA
15
Show member pathways
12.63 AKT1 CTNNB1 EGFR ERBB2 KRAS PIK3CA
16 12.58 BRCA1 EGFR ERBB2 KRAS PIK3CA
17
Show member pathways
12.58 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 EGFR
18
Show member pathways
12.56 AKT1 EGFR ERBB2 KRAS PIK3CA
19
Show member pathways
12.54 AKT1 EGFR ERBB2 KRAS PIK3CA
20 12.48 AKT1 CTNNB1 KRAS PIK3CA RRAS2
21
Show member pathways
12.47 AKT1 CTNNB1 EGFR ERBB2 KRAS PIK3CA
22
Show member pathways
12.46 CTNNB1 EGFR KRAS RRAS2
23
Show member pathways
12.46 AKT1 EGFR KRAS PIK3CA RRAS2
24
Show member pathways
12.45 AKT1 BRCA1 CTNNB1 KRAS PIK3CA
25
Show member pathways